Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
The last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta. What does this mean? Here's Dr. Leighl's summary of the trial and her discussion of its implications.
[powerpress]
Dr. Leighl Highlights in LC 2012 Pt 5 Maint Rx Audio Podcast
Dr. Leighl Highlights in LC 2012 Pt 5 Maint Rx Figs
This was the last of the highlights she covered, so we'll move to another webinar soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi James Anthony, I'm so sorry you are going through this and so very young. It' s true that some people benefit for years with chemo and targeted therapies. With the...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.